Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...

Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

GLP-1 drugs, synthetic versions of a natural hormone, are revolutionizing weight loss and type 2 diabetes treatment. By ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

NEW YORK (AP) — The U.S. stock market sank from its record heights on Thursday, as Wall Street sifted through mixed ...